INVASIVE BREAST CARCINOMA

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps shrink tumors more effectively in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or chemo plus atezoliz…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that still remains after initial chemotherapy and surgery. About 415 participants with stage II or III bre…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can boost the body's immune attack on HER2-negative breast cancer. About 46 adults with locally advanced disease will receive this short course, then proceed to usu…

This study tests a new way to give radiation to women with early-stage breast cancer. Instead of treating the whole breast, it targets only the area where the cancer started and uses higher doses over fewer sessions. The goal is to see if this approach causes fewer side effects w…

This study tests a drug called sacituzumab govitecan in 44 people with HER2-negative breast cancer that has spread to the brain. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering chemotherapy directly to them. The goal is to see if it can shr…

This study looks at whether combining a nightly fasting period with the diabetes drug metformin can slow the growth of early-stage breast cancer. About 120 women with hormone-sensitive breast cancer or a pre-cancer condition called DCIS will follow a fasting schedule and take met…

This study tested whether adding trastuzumab to standard chemotherapy before surgery helps shrink breast tumors more effectively. About 92 women with early-stage breast cancer (some HER2-positive, some HER2-negative) took part. The goal was to see if the combination reduces the a…

This study tests whether a shorter course of radiation (hypofractionated) after mastectomy works as well as standard radiation to prevent breast cancer from coming back. About 900 people with stage II to IIIA breast cancer took part. The shorter schedule aims to cause fewer side …

This phase 3 trial tests whether adding tucatinib to the standard drug T-DM1 can better prevent HER2-positive breast cancer from returning in high-risk patients. About 1,056 participants who still have cancer after initial treatment will receive either T-DM1 alone or T-DM1 plus t…

This study tests whether combining the immunotherapy drug avelumab with other medications can help people with advanced triple-negative breast cancer. About 145 adults with stage IV or inoperable breast cancer will receive one of several drug combinations. The goal is to see if t…

This study tested a shorter course of radiation (hypofractionation) for women with breast cancer that has spread to lymph nodes. The goal was to see if this approach reduces long-term side effects like arm swelling (lymphedema) while still controlling cancer. About 137 women part…

This study tests whether giving radiation therapy before surgery can shrink hormone receptor-positive, HER2-negative breast tumors. About 25 adults with this type of breast cancer will receive radiation to the tumor area before their surgery. The goal is to see if this approach r…

This study tests a combination of targeted drugs (ribociclib, tucatinib, trastuzumab) with or without hormone therapy (fulvestrant) for HER2-positive breast cancer. In the first part, it checks safety in patients whose cancer has spread. In the second part, it compares this combo…

This study looks at whether the drug ixabepilone can help people with HER2-negative breast cancer who still have cancer after standard chemotherapy. About 116 participants will either receive ixabepilone or be observed. The goal is to see if the drug can reduce the risk of cancer…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or aromatase inhibitors) either alone or with chemotherapy. The goal was to …

This study looks at whether people with HER2-positive breast cancer (stage II to IIIa) who have no cancer left after initial chemotherapy and targeted therapy can safely receive fewer chemotherapy drugs after surgery. About 2,175 participants will get paclitaxel, trastuzumab, and…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent triple-negative breast cancer from returning. About 1,155 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or a placebo. …

This early-phase study tests the safety and best doses of three drugs—entinostat, nivolumab, and ipilimumab—given together to people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to see if this combination can help the immune system figh…

This study compares two different chemotherapy combinations given before surgery for a fast-growing, hard-to-treat type of breast cancer called triple-negative inflammatory breast cancer. Researchers want to see if adding a targeted drug called panitumumab to standard chemotherap…

This study tests whether a special PET/CT scan (FDG-PET/CT) can predict how well HER2-positive breast cancer responds to chemotherapy before surgery. About 235 adults with stage II-III breast cancer will get the scan early in treatment. The goal is to see if the scan can help doc…

This study looks at whether giving an extra dose of radiation before breast cancer surgery is safe and helps doctors target the tumor better. It involves about 100 people with early-stage breast cancer that hasn't spread. The goal is to see if this approach leads to fewer side ef…

This study compares two skin creams, Aquaphor and Miaderm, to see which one better treats the painful skin rash caused by radiation therapy in breast cancer patients. About 208 women getting radiation after breast cancer surgery will use one of the creams and report their skin re…

This study compares a 3-week radiation schedule to the usual 5-week schedule for breast cancer patients who need radiation to the lymph nodes near the breast. The goal is to see if the shorter treatment is just as effective at preventing cancer from coming back, while also reduci…

This study looks at how well proton beam radiation works for early-stage breast cancer (stages 0 to II) and what side effects it causes. Researchers want to see if this precise type of radiation can kill cancer cells while causing less damage to healthy tissue and improving how t…

This study tests whether adding text message reminders and telephone counseling helps breast cancer patients take their daily hormone therapy pills more consistently. About 1,167 women with early-stage hormone receptor-positive breast cancer will be followed for up to two years. …

This study tested whether a shorter course of higher-dose radiation (hypofractionated) works as well as standard longer radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer took part. The goal was to see if the sho…

This study looks at why women in the Hauts-de-France region of France may wait longer to start breast cancer treatment, which could explain higher death rates there. Researchers will track 500 women recently diagnosed with invasive breast cancer, measuring delays from first sympt…

This study looks at whether a genetic test can identify African American women with breast cancer who are more likely to develop nerve damage from taxane chemotherapy. Researchers compare two chemo drugs, docetaxel and paclitaxel, to see which causes fewer nerve problems. About 2…

This study planned to give high doses of vitamin D to women with breast cancer before their surgery to see how it affected cancer cells. Researchers wanted to measure changes in certain proteins and receptors linked to cancer growth. The study was withdrawn before any participant…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…

This study looks at whether testing tumor genes can help predict if HER2-negative breast cancer will respond to standard treatments like chemotherapy or hormone therapy. About 1,100 people with early-stage breast cancer (stages I to III) will have their tumor samples analyzed. Th…

This study looks at how chemotherapy given before surgery affects the immune system in people with operable breast cancer. Researchers will collect blood samples from 38 patients to see how different immune cells change during treatment. The goal is to understand why some patient…

This study aims to create a large collection of blood and tumor samples from 300 people whose breast cancer has spread or returned. By linking these samples with medical information, researchers hope to learn why the cancer spreads and why people respond differently to treatments…

This study looks at how a medicated gel (afimoxifene) is absorbed through the skin of the breast in women who have had radiation therapy for breast cancer. Researchers want to understand if skin type, blood vessels, or past radiation affect how much of the drug reaches breast tis…